Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues by 2030, bolstered by recently launched therapies such as the hemophilia treatment Altuviiio (Fc-VWF-XTEN fusion protein), the cytolytic antibody Sarclisa (isatuximab), and Tzield (teplizumab) for type 1 diabetes management. Additional contributions are expected from upcoming treatments for immune-mediated diseases, including amlitelimab, frexalimab, itepekimab, and tolebrutinib. Furthermore, Sanofi projects an additional EUR 10 billion in annual revenue from its vaccine division by 2030.
The company also announced plans for a 50% increase in late-stage trials over the next two years, with 25 mid- to late-stage readouts and up to 19 product filings anticipated.
In a similar vein, The public data reveals that Johnson & Johnson (J&J, NYSE: JNJ) has also announced over 15 potential blockbusters, with more than 10 assets expected to surpass USD 5 billion in sales by 2030.- Flcube.com
